FGF1 and diabetic foot: Promising clinical results have been achieved, for example, using fibroblast growth factor-1 (FGF-1): FGF-1 is currently in NIH phase II clinical trials for the pro-angiogenic treatment of coronary heart disease (NCT00117936) and wound healing in diabetic foot ulcers (NCT00916292).